272 related articles for article (PubMed ID: 31822498)
1. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR
Lehmann BD; Abramson VG; Sanders ME; Mayer EL; Haddad TC; Nanda R; Van Poznak C; Storniolo AM; Nangia JR; Gonzalez-Ericsson PI; Sanchez V; Johnson KN; Abramson RG; Chen SC; Shyr Y; Arteaga CL; Wolff AC; Pietenpol JA;
Clin Cancer Res; 2020 May; 26(9):2111-2123. PubMed ID: 31822498
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
[TBL] [Abstract][Full Text] [Related]
3. Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?
Sharifi MN; O'Regan RM; Wisinski KB
Clin Breast Cancer; 2023 Dec; 23(8):813-824. PubMed ID: 37419745
[TBL] [Abstract][Full Text] [Related]
4. Identification of a targetable JAK-STAT enriched androgen receptor and androgen receptor splice variant positive triple-negative breast cancer subtype.
Asemota S; Effah W; Young KL; Holt J; Cripe L; Ponnusamy S; Thiyagarajan T; Hwang DJ; He Y; Mcnamara K; Johnson D; Wang Y; Grimes B; Khosrosereshki Y; Hollingsworth TJ; Fleming MD; Pritchard FE; Hendrix A; Khan F; Fan M; Makowski L; Yin Z; Sasano H; Hayes DN; Pfeffer LM; Miller DD; Narayanan R
Cell Rep; 2023 Dec; 42(12):113461. PubMed ID: 37979170
[TBL] [Abstract][Full Text] [Related]
5. Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification.
Lee M; Yoo TK; Chae BJ; Lee A; Cha YJ; Lee J; Ahn SG; Kang J
Sci Rep; 2024 May; 14(1):11278. PubMed ID: 38760384
[TBL] [Abstract][Full Text] [Related]
6. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.
Ganesan P; Moulder S; Lee JJ; Janku F; Valero V; Zinner RG; Naing A; Fu S; Tsimberidou AM; Hong D; Stephen B; Stephens P; Yelensky R; Meric-Bernstam F; Kurzrock R; Wheler JJ
Mol Cancer Ther; 2014 Dec; 13(12):3175-84. PubMed ID: 25253784
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes.
Basho RK; Zhao L; White JB; Huo L; Bassett RL; Mittendorf EA; Thompson A; Litton JK; Ueno N; Arun B; Lim B; Valero V; Tripathy D; Zhang J; Adrada BE; Santiago L; Ravenberg E; Seth S; Yam C; Moulder SL; Damodaran S
JCO Precis Oncol; 2024 Mar; 8():e2300124. PubMed ID: 38484209
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-Inducible Expression of Annexin A6 Enhances the Resistance of Triple-Negative Breast Cancer Cells to EGFR and AR Antagonists.
Williams SD; Smith TM; Stewart LV; Sakwe AM
Cells; 2022 Sep; 11(19):. PubMed ID: 36230969
[TBL] [Abstract][Full Text] [Related]
9. Incidence and Prognostic Significance of Androgen Receptors (AR) in Indian Triple-Negative Breast Cancer (TNBC).
Mishra A; Mishra SK; Sharanappa V; Krishnani N; Kumari N; Agarwal G
Indian J Surg Oncol; 2024 Jun; 15(2):250-257. PubMed ID: 38741650
[TBL] [Abstract][Full Text] [Related]
10. Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy.
Zhao YX; Wang H; Zhang SW; Zhang WX; Jiang YZ; Shao ZM
Cancer Cell Int; 2024 Apr; 24(1):131. PubMed ID: 38594722
[TBL] [Abstract][Full Text] [Related]
11. Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.
Liu Y; Zhu XZ; Xiao Y; Wu SY; Zuo WJ; Yu Q; Cao AY; Li JJ; Yu KD; Liu GY; Wu J; Sun T; Cui JW; Lv Z; Li HP; Zhu XY; Jiang YZ; Wang ZH; Shao ZM
Cell Res; 2023 May; 33(5):389-402. PubMed ID: 36973538
[TBL] [Abstract][Full Text] [Related]
12. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
13. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Schmid P; Abraham J; Chan S; Wheatley D; Brunt AM; Nemsadze G; Baird RD; Park YH; Hall PS; Perren T; Stein RC; Mangel L; Ferrero JM; Phillips M; Conibear J; Cortes J; Foxley A; de Bruin EC; McEwen R; Stetson D; Dougherty B; Sarker SJ; Prendergast A; McLaughlin-Callan M; Burgess M; Lawrence C; Cartwright H; Mousa K; Turner NC
J Clin Oncol; 2020 Feb; 38(5):423-433. PubMed ID: 31841354
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J;
N Engl J Med; 2020 Feb; 382(9):810-821. PubMed ID: 32101663
[TBL] [Abstract][Full Text] [Related]
15. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
Eikesdal HP; Yndestad S; Elzawahry A; Llop-Guevara A; Gilje B; Blix ES; Espelid H; Lundgren S; Geisler J; Vagstad G; Venizelos A; Minsaas L; Leirvaag B; Gudlaugsson EG; Vintermyr OK; Aase HS; Aas T; Balmaña J; Serra V; Janssen EAM; Knappskog S; Lønning PE
Ann Oncol; 2021 Feb; 32(2):240-249. PubMed ID: 33242536
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Garrido-Castro AC; Saura C; Barroso-Sousa R; Guo H; Ciruelos E; Bermejo B; Gavilá J; Serra V; Prat A; Paré L; Céliz P; Villagrasa P; Li Y; Savoie J; Xu Z; Arteaga CL; Krop IE; Solit DB; Mills GB; Cantley LC; Winer EP; Lin NU; Rodon J
Breast Cancer Res; 2020 Nov; 22(1):120. PubMed ID: 33138866
[TBL] [Abstract][Full Text] [Related]
17. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
18. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline
Tung N; Arun B; Hacker MR; Hofstatter E; Toppmeyer DL; Isakoff SJ; Borges V; Legare RD; Isaacs C; Wolff AC; Marcom PK; Mayer EL; Lange PB; Goss AJ; Jenkins C; Krop IE; Winer EP; Schnitt SJ; Garber JE
J Clin Oncol; 2020 May; 38(14):1539-1548. PubMed ID: 32097092
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.
Yuan Y; Lee JS; Yost SE; Frankel PH; Ruel C; Egelston CA; Guo W; Gillece JD; Folkerts M; Reining L; Highlander SK; Robinson K; Padam S; Martinez N; Tang A; Schmolze D; Waisman J; Sedrak M; Lee PP; Mortimer J
Oncologist; 2021 Feb; 26(2):99-e217. PubMed ID: 33141975
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
